紫杉醇联合顺铂同步放化疗治疗局部晚期非小细胞肺癌的疗效观察  

Curative Effect Observation of Concurrent Chemoradiotherapy with Paclitaxel and Cisplatin in the Treatment of Locally Advanced Non-Small Cell Lung Cancer

作　　者：罗劼妍 黄浩[1] 黄胜兰[1] 陈炎[1] 陈洁[2] 

机构地区：[1]宜宾市第二人民医院肿瘤一科,四川宜宾644000 [2]宜宾市第二人民医院肿瘤二科,四川宜宾644000

出　　处：《锦州医科大学学报》2017年第6期18-21,共4页Journal of Jinzhou Medical University

摘　　要：目的探讨紫杉醇联合顺铂同步放化疗治疗局部晚期非小细胞肺癌(NSCLC)的临床疗效和安全性。方法选择2014年3月至2016年3月期间来我院治疗的局部晚期NSCLC患者72例作为研究对象,根据随机数字表法将其分为对照组和观察组,各36例。对照组采用单纯的放疗方案治疗,观察组在放疗的基础上给予紫杉醇联合顺铂化疗,化疗周期为2w。化疗结束后,对比两组治疗有效率和不良反应发生情况。对所有患者进行为期1年的随访,对比两组1年生存率。结果观察组治疗有效率为88.89%(32/36),高于对照组的66.67%(24/36),差异有统计学意义(P<0.05)。观察组血红蛋白减少、血小板减少、白细胞减少、肌肉关节疼痛Ⅲ~Ⅳ级发生率高于对照组,差异有统计学意义(P<0.05);但两组患者脱发、腹泻、恶心呕吐发生率比较差异无统计学意义(P>0.05)。观察组1年生存率为55.56%(20/36),高于对照组的30.56%(11/36),差异有统计学意义(P<0.05)。结论紫杉醇联合顺铂同步放化疗治疗局部晚期NSCLC有较好的疗效,且能有效的延长患者生存时间,但不良反应相对严重,临床上应根据患者的具体病情选择治疗方案。Objective To investigate the clinical efficacy and safety of concurrent chemoradiotherapy with paclitaxel and cisplatin in the treatment of locally advanced non-small cell lung cancer（ NSCLC）. Methods 72 patients with locally advanced NSCLC who were treated in our hospital from March 2014 to March 2016 were selected as the subjects,and they were divided into control group and observation group with 36 cases in each group according to the method of random number table. The control group was treated with radiotherapy alone; the observation group was treated with paclitaxel combined with cisplatin chemotherapy on the basis of radiotherapy,with the chemotherapy cycle of 2 weeks. After the chemotherapy,the effective rate of treatment and adverse reaction were compared between the two groups. All patients were followed up for 1 year to compare the 1-year survival rate of the two groups. Results The effective rate of the observation group was 88. 89%（ 32/36）,which was higher than that of the control group（ 66. 67%,24/36）,and the difference was statistically significant（ P〈0. 05）. The reduction of hemoglobin,thrombocytopenia,white blood cells,and the incidence rates of grades 3 ~ 4 muscle and joint pain in the observation group was higher than those in the control group,and the difference was statistically significant（ P〈0. 05）. However,there was no statistically significant difference between the two groups in the incidence rates of hair loss,diarrhea,nausea and vomiting（ P 〉 0. 05）. 1-year survival rate of the observation group was55. 56%（ 20/36）,which was higher than that of the control group（ 30. 56%,11/36）,and the difference was statistically significant（ P〈0. 05）. Conclusion Concurrent chemotherapy with paclitaxel and cisplatin in the treatment of locally advanced NSCLC has a good curative effect,and can effectively prolong survival of the patients. However,the adverse reactions are relatively serious. Clinical treatment regimen should be selected according to the specifi

关 键 词：非小细胞肺癌 顺铂 紫杉醇 局部 

分 类 号：R978.7[医药卫生—药品]